• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝性脑病作为终末期肝病患者生存的预测指标。

Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease.

作者信息

Stewart Charmaine A, Malinchoc Michael, Kim W Ray, Kamath Patrick S

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Liver Transpl. 2007 Oct;13(10):1366-71. doi: 10.1002/lt.21129.

DOI:10.1002/lt.21129
PMID:17520742
Abstract

Hepatic encephalopathy (HE) is an important component of hepatic decompensation, which reduces survival in patients with cirrhosis. The Model for End-Stage Liver Disease (MELD) score has been used to predict survival of patients with cirrhosis. The aims of this study were to determine whether HE is a predictor of survival of patients with cirrhosis and to examine the degree to which HE may add to the survival prediction of MELD. Patients with end-stage liver disease whose data were included in 2 databases were included in the analysis: 223 patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) insertion, and 271 patients hospitalized with hepatic decompensation. In univariate analysis, HE grade 3 or higher was associated with a 3.7-fold (95% confidence interval, 1.9-7.3, P<0.01) increase in the risk of death in the TIPS patients and HE grade 2 or higher was associated 3.9-fold increase (95% confidence interval [95% CI], 2.6-5.7, P<0.01) in hospitalized patients. As expected, MELD and Child-Turcotte-Pugh scores (with and without HE included) were also markedly associated with survival. When HE (grade 2 or higher) and MELD were considered together, HE remained strongly statistically significant in the hospitalized patients (hazard ratio=2.6, 95% CI, 1.7-3.8, P<0.01). The effect became smaller in the TIPS patients (hazard ratio=1.1; 95% CI, 0.7-1.6, P=0.76). In conclusion, this retrospective study demonstrates that HE is an important event in the natural history of cirrhosis that affects subsequent survival of patients. HE may provide additional prognostic information independent of MELD, which warrants prospective validation.

摘要

肝性脑病(HE)是肝脏失代偿的一个重要组成部分,它会降低肝硬化患者的生存率。终末期肝病模型(MELD)评分已被用于预测肝硬化患者的生存率。本研究的目的是确定HE是否为肝硬化患者生存率的预测指标,并探讨HE在多大程度上可补充MELD对生存率的预测。纳入分析的是数据包含在2个数据库中的终末期肝病患者:223例行经颈静脉肝内门体分流术(TIPS)的患者以及271例因肝脏失代偿住院的患者。在单因素分析中,3级或更高等级的HE与TIPS患者死亡风险增加3.7倍(95%置信区间,1.9 - 7.3,P<0.01)相关,2级或更高等级的HE与住院患者死亡风险增加3.9倍(95%置信区间[95%CI],2.6 - 5.7,P<0.01)相关。正如预期的那样,MELD和Child - Turcotte - Pugh评分(包括和不包括HE)也与生存率显著相关。当将HE(2级或更高等级)和MELD一起考虑时,HE在住院患者中仍具有高度统计学显著性(风险比=2.6,95%CI,1.7 - 3.8,P<0.01)。在TIPS患者中这种效应变小(风险比=1.1;95%CI,0.7 - 1.6,P = 0.76)。总之,这项回顾性研究表明,HE是肝硬化自然病程中的一个重要事件,会影响患者的后续生存。HE可能提供独立于MELD的额外预后信息,这值得进行前瞻性验证。

相似文献

1
Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease.肝性脑病作为终末期肝病患者生存的预测指标。
Liver Transpl. 2007 Oct;13(10):1366-71. doi: 10.1002/lt.21129.
2
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.肝静脉压力梯度可预测代偿期肝硬化患者的临床失代偿情况。
Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21.
3
Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites.终末期肝病模型(MELD)评分与肝性脑病(由脑电图和神经心理测试定义)及腹水的关系。
Am J Gastroenterol. 2003 Jun;98(6):1395-9. doi: 10.1111/j.1572-0241.2003.07466.x.
4
Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score.终末期肝病模型(DeltaMELD)评分随时间增加作为晚期肝硬化患者预后预测指标的评估:危险因素分析及与初始MELD和Child-Turcotte-Pugh评分的比较
J Hepatol. 2005 Jun;42(6):826-32. doi: 10.1016/j.jhep.2005.01.019. Epub 2005 Mar 31.
5
MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures.终末期肝病模型(MELD)评分作为接受择期经颈静脉肝内门体分流术(TIPS)患者早期死亡的预测指标。
Cardiovasc Intervent Radiol. 2005 May-Jun;28(3):307-12. doi: 10.1007/s00270-004-0145-y.
6
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.预测代偿期丙型肝炎病毒(HCV)所致肝硬化患者的死亡风险:一项长期前瞻性研究。
Am J Gastroenterol. 2009 May;104(5):1147-58. doi: 10.1038/ajg.2009.31. Epub 2009 Apr 7.
7
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting.MELD、Child-Pugh和埃默里模型在经颈静脉肝内门体分流术患者生存预测中的比较
Am J Gastroenterol. 2003 May;98(5):1167-74. doi: 10.1111/j.1572-0241.2003.07515.x.
8
Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score.肝硬化的病因对终末期肝病模型评分预测的生存率有影响。
Eur J Clin Invest. 2009 Jan;39(1):65-71. doi: 10.1111/j.1365-2362.2008.02063.x.
9
The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey.终末期肝病模型-钠评分是肝细胞癌独立的短期和长期预后预测指标:一项前瞻性调查。
Dig Liver Dis. 2008 Nov;40(11):882-9. doi: 10.1016/j.dld.2008.01.015. Epub 2008 Mar 12.
10
Independent prognostic factors in patients with liver cirrhosis.肝硬化患者的独立预后因素。
Hepatogastroenterology. 2008 May-Jun;55(84):1034-40.

引用本文的文献

1
Beyond Liver Function: .肝功能之外:
Sultan Qaboos Univ Med J. 2025 May 2;25(1):266-275. doi: 10.18295/2075-0528.2837.
2
Comparing efficacy of different scoring models to predict hepatic encephalopathy after TIPS in cirrhotic patients.比较不同评分模型预测肝硬化患者经颈静脉肝内门体分流术后肝性脑病的疗效。
Ann Med. 2025 Dec;57(1):2514082. doi: 10.1080/07853890.2025.2514082. Epub 2025 Jun 6.
3
TIPS and hepatic encephalopathy in patients with cirrhosis.肝硬化患者的经颈静脉肝内门体分流术(TIPS)与肝性脑病
Metab Brain Dis. 2025 Feb 4;40(2):117. doi: 10.1007/s11011-025-01541-w.
4
Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China.400 或 800ml 细菌计数粪菌移植治疗复发性肝性脑病的疗效和安全性比较:中国多中心前瞻性随机对照临床试验。
Trials. 2024 Nov 27;25(1):799. doi: 10.1186/s13063-024-08578-9.
5
Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis before and after Direct-Acting Antivirals.直接作用抗病毒药物治疗前后慢性丙型肝炎肝硬化患者的肝脏硬度评估
Microorganisms. 2024 Jul 12;12(7):1418. doi: 10.3390/microorganisms12071418.
6
Outcome Predictors of Acute-on-Chronic Liver Failure: A Narrative Review.慢加急性肝衰竭的预后预测因素:一项叙述性综述
Cureus. 2024 Jun 4;16(6):e61655. doi: 10.7759/cureus.61655. eCollection 2024 Jun.
7
A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis.一项稳健的聚类分层策略揭示了急性失代偿性肝硬化中独特的患者亚组。
J Transl Med. 2024 Jun 27;22(1):599. doi: 10.1186/s12967-024-05386-2.
8
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.利福昔明预防和治疗肝硬化患者肝性脑病。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.
9
Hepatic Encephalopathy in Cirrhotic Patients With Bacterial Infections: Frequency, Clinical Characteristics, and Prognostic Relevance.肝硬化合并细菌感染患者的肝性脑病:发生率、临床特征及预后相关性
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):559-567. doi: 10.1016/j.jceh.2023.01.004. Epub 2023 Jan 17.
10
The Glymphatic System May Play a Vital Role in the Pathogenesis of Hepatic Encephalopathy: A Narrative Review.糖胺聚糖系统可能在肝性脑病的发病机制中起关键作用:叙述性综述。
Cells. 2023 Mar 23;12(7):979. doi: 10.3390/cells12070979.